Immunohistochemical features of actinic keratosis.

Authors

  • O. O. Oshivalova State Scientific Institution “Scientific and Practical Centre of Preventive and Clinical Medicine” of the State Administration, Kyiv Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine https://orcid.org/0000-0002-0395-0269
  • L. D. Kaluzhna Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • I. S. Shponka State Institution "Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine", Dniprо, Ukraine https://orcid.org/0000-0002-7561-6489
  • O. V. Poslavska State Institution "Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine", Dniprо, Ukraine https://orcid.org/0000-0002-3133-8413

DOI:

https://doi.org/10.26641/1997-9665.2019.3.7-21

Keywords:

actinic keratosis, cutaneous squamous cell carcinoma, cell cycle, apoptosis pathways, carcinogenesis

Abstract

Background. Skin damage by type of actinic keratosis (AK) and squamous cell carcinoma in situ (SCCis) are considered to be precursors to cSCC. A common theory about the gradual transition from normal skin to AK and cSCC. Some scientists believe that AK is the same cancer as cSCC. Objective. To investigate the complex of histological, immunohistochemical characteristics of observations of areas of AK, SCCis and cSCC with the purpose of further improvement of preventive measures. Methods. Bioassays of 20 (50%) patients with AK were used, 10 (25%) were SCCis, and 10 (25%) were CCSCs. The levels of epidermal dysplasia (KIN) have been determined. Light microscopy was performed with a Zeiss Primo Star light microscope using × 10, × 20, × 40 lenses, and a morphometric examination was performed using a Zeiss Primo Star microscope camera - Axiocam ERC 5s with ZEN 2 blue edition licensed software. Statistical processing of the material was performed using Microsoft Office Exel software. Results. When comparing the expression levels of the investigated markers in the AK foci, the "cancer field" and the SCC, a significant difference occurred only in the expression level of pcna (p = 0.014 and p = 0.011). With the increase in the level of dysplasia of the epidermis there is a tendency to increase the level of bcl-2 (R2 = 0.815), p53 (R2 = 0.744) vegf mean (R2 = 0.680). Trends in increasing pcna and vegf levels against the background of decreasing levels of bcl-2, p53, and p27 in the SCC zone (R2 = 1.0). Conclusion. The study confirms the scientific opinion about the closeness of immunohistochemical changes in the focus of AK and cSCC.

References

  1. Abbastabar M, Kheyrollah M, Azizian K, Bagherlou N, Tehrani SS, Maniati M, Karimian A. Multiple functions of p27 in cell cycle, apoptosis, epigenetic modification and transcriptional regulation for the control of cell growth: A double-edged sword protein. DNA Repair (Amst). 2018;69:63-72.
  2. Dai L, Liu Y, Liu J, Wen X, Xu Z, Wang Z, Sun H, Tang S, Maguire AR, Quan J, Zhang H, Ye T. A novel cyclinE/cyclinA-CDK inhibitor targets p27(Kip1) degradation, cell cycle progression and cell survival: implications in cancer therapy. Cancer Lett. 2013;333(1):103-112.
  3. Ra SH, Li X, Binder S. Molecular discrimination of cutaneous squamous cell carcinoma from actinic keratosis and normal skin. Modern Pathology. 2011;24:963–973.
  4. Wander SA, Zhao D, Slingerland JM. p27: A Barometer of Signaling Deregulation and Potential Predictor of Response to Targeted Therapies. Clin Cancer Res. 2011;17(1):12–18.
  5. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Can-cer. 2008;8:253–267.
  6. Catzavelos C, Bhattacharya N, Ung YC. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med. 1997;3:227–230.
  7. Han S, Park K, Kim HY, Lee MS, Kim HJ, Kim YD. Reduced expression of p27Kip1 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentia-tion. Breast Cancer Res Treat. 1999;55:161–167.
  8. Sui L, Dong Y, Ohno M. Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol Oncol. 2001;83:56–63.
  9. Korkolopoulou P, Vassilopoulos I, Konstantinidou AE. The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients. Gynecol Oncol. 2002;85:404–414.
  10. Haider AS, Peters SB, Kaporis H. Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol. 2006;126:869–881.
  11. Legg JA, Herbert JM, Clissold P. Slits and roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis. 2008;11:13–21.
  12. Liu Z, Yang X, Tan F. Molecular cloning and characterization of human Castor, a novel hu-man gene upregulated during cell differentiation. Biochem Biophys Res Commun. 2006;344:834–844.
  13. Jin T, Fantus GI, Sun J. Wnt and beyond Wnt: multiple mechanisms control the transcription-al property of beta-catenin. Cell Sig-nal.2008;20:1697–1704.
  14. Paul S, Dey A. Wnt signaling and cancer development: therapeutic implication. Neoplasma. 2008;55:165–176.
  15. Brash DE, Ziegler A, Jonason AS. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc. 1996;1:136–142.
  16. Li Т, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R, Gu W. Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence. Cell. 2012;149(6):1269-1283.
  17. Benjamin CL, Melnikova VO, Ananthaswamy HN. P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol. 2008;624:265–282.
  18. Bachs O, Gallastegui E,Orlando S, Bigas A, Morante-Redolat JM, Serratosa J, Fariñas I, Aligué R, Pujol MJ. Role of p27Kip1 as a transcriptional regulator. Oncotarget. 2018;9(40):26259–26278.
  19. Bologna-Molina R, Mosqueda-Taylor A, Molina-Frechero N, Mori-Estevez AD, Sánchez-Acuña G. Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumor. Med Oral Patol Oral Cir Bucal. 2013;18(2):e174–e179.
  20. Kelman Z. PCNA: structure, functions and interactions. Oncogene. 1997;14:629–40.
  21. de Oliveira MG, Lauxen-Ida S, Chaves AC, Rados PV, Sant'AnaFilho M. Immunohistochemical analysis of the patterns of p53 and PCNA expression in odontogenic cystic lesions. Med Oral Patol Oral Cir Bucal. 2008;13:E275–280.
  22. Mighell A. PCNA and p53. Eur J Cancer B Oral Oncol. 1995;31B:403–404.
  23. Juríková M, Danihel Ľ, Polák Š, Varga I. Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 2016;118:544–552.
  24. Qiu X, Mei J, Yin J, Wang H, Wang J. Correlation analysis between expression of PCNA, Ki 67 and COX-2 and X-ray features in mammography in breast cancer. Oncology Letters. 2017;14(3):2912-2918.
  25. Bouchbika Z, Benchakroun N, Taleb A, Jouhadi H, Tawfiq N, Sahraoui S, Benider A. Association between overexpression of Her-2 and other clinicopathologic prognostic factors in breast cancer in Morocco. J Cancer Ther. 2012;3:787–792.
  26. Qu DW, Liu Y, Wang L, Xiong Y, Zhang CL, Gao DS. Glial cell line-derived neurotrophic factor promotes proliferation of neuroglioma cells by up-regulation of cyclins PCNA and Ki-67. Eur Rev Med Pharmacol Sci. 2015;19:2070–2075.
  27. Maga G, Hübscher U. Proliferating cell nu-clear antigen (PCNA): a dancer with many partners. Journal of Cell Science. 2003;116:3051-3060.
  28. Ferrara N. Vascular Endothelial Growth Factor as a target foranticancer therapy. Oncologist. 2004;9:2–10.
  29. Rak J, Yu JL, Klement G. Oncogenes and angiogenesis:signaling three-dimensional tumor growth. J. Invest. Dermatol.Symp. Proc. 2000;5(1):24–33.
  30. Miletic H. Anti-VEGF therapies for malignant glioma:treatment effects and escape mechanisms. Expert Opin. 2009;13(4):455–468.
  31. Guo D, Murdoch C, Liu T, Qu J. Therapeutic Angiogenesis of Chinese Herbal Medicines in Ischemic Heart Disease: A Review. Frontiers in Pharmacology.2018;9:428.
  32. Poon RT, Fan ST, Wong J. Clinical implications of circulatingangiogenic factors in cancer patients. J. Clin. Oncol. 2001;19(4):1207–1225.
  33. Abramsson A, Berlin O, Papayan H. Analysis of mural cell recruitment to tumor vessels. Circulation. 2002;105(1):112–117.
  34. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma – like vessels by VEGF with-drawal. Proc. Natl. Acad. Sci. USA. 1997;94(16):8761–8766.
  35. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factorinduces expression of the antiapoptotic proteins Bcl-2 and A1 invascular endothelial cells. J. Biol. Chem. 1998;273(21):13313–13316.
  36. Gerber HP, McMurtrey A, Kowalski J. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway. Require-ment for Flk-1/KDR activation. J. Biol. Chem. 1998;273(46):30336–30343.
  37. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews Molecular Cell Biolo-gy. 2008;9:47-59.
  38. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Direct Activation of Bax by p53 Mediates Mi-tochondrial Membrane Permeabilization and Apop-tosis. Science. 2004;303(5660):1010-1014.
  39. Kang MH, Reynolds CP. Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy. Clinical Cancer Re-search. 2009;15:1126-32.
  40. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Nature Oncogene. 2008;27:6398-6406.
  41. Tsujimoto Y. Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells. 1998;3:697-707.
  42. Ludwig LM, Nassin ML, Hadji A, LaBelle JL. Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation. Frontiers in Pediat-rics. 2016;4:135.
  43. ChenA, Madu CO, Lu Y. The Functional Role of Bcl-2 Family of Proteins in the Immune System and Cancer. Oncomedicine. 2019;4:17-26.
  44. Hameetman L, Commandeur S, Bouwes Bavinck JN, Wisgerhof HC, de Gruijl FR., Willemze R, Mullenders L, Tensen CP, Vrieling H. Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients. BMC Cancer. 2013;13:58.
  45. Padilla RS, Sebastian S, Jiang Z, NindlI Larson R. Gene Expression Patterns of Normal Hu-man Skin, Actinic Keratosis, and Squamous Cell Carcinoma. Arch dermatol.2010;146(3):288-293.
  46. Poslavska OV. [Methodology for the use of software for the analysis of digital micrographs on the base of pathomorphology course in order to increase the professional level of students and scientists]. Morphologia. 2015;9(3):122-6. Ukrainian

Downloads

How to Cite

Oshivalova, O. O., Kaluzhna, L. D., Shponka, I. S., & Poslavska, O. V. (2019). Immunohistochemical features of actinic keratosis. Морфологія / Morphologia / Morfologìâ, 13(3), 7–21. https://doi.org/10.26641/1997-9665.2019.3.7-21

Issue

Vol. 13 No. 3 (2019)

Section

Статті

License

Copyright (c) 2019 Morphologia

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.
        By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world. 
        The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.